

<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an analysis of covariance (ANCOVA) model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0001
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on ANCOVA model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	< .0001
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	< .0001

Method	ANCOVA
Confidence interval	